the AVAIL Trial

Savara Provides Pipeline and Business Update

Retrieved on: 
Thursday, December 10, 2020
Research, Infectious diseases, FDA, Clinical trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Savara, Gratitude, APAP, the AVAIL Trial, Savara

I am grateful for the opportunity to be a part of the Savara team, said Matt Pauls, Chairman and CEO, Savara.

Key Points: 
  • I am grateful for the opportunity to be a part of the Savara team, said Matt Pauls, Chairman and CEO, Savara.
  • Finally, I am excited to continue leading Savara and look forward to working on behalf of the aPAP community while creating shareholder value.
  • We extend our gratitude to the patients and clinical trial staff who participated in AVAIL, said Badrul Chowdhury, Chief Medical Officer, Savara.
  • Savara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.